Citigroup Analysts Give CVS Health (CVS) a $76.00 Price Target

Citigroup set a $76.00 target price on CVS Health (NYSE:CVS) in a report released on Monday. The firm currently has a hold rating on the pharmacy operator’s stock.

A number of other analysts also recently commented on the stock. Leerink Swann set a $85.00 price target on shares of CVS Health and gave the stock a buy rating in a research report on Monday. Needham & Company LLC boosted their price target on shares of CVS Health from $79.00 to $85.00 and gave the stock a buy rating in a research report on Monday. Deutsche Bank began coverage on shares of CVS Health in a research report on Monday. They set a buy rating and a $90.00 price target on the stock. Loop Capital dropped their price target on shares of CVS Health from $83.00 to $73.00 and set a hold rating on the stock in a research report on Tuesday, November 7th. Finally, Jefferies Group dropped their price target on shares of CVS Health from $86.00 to $76.00 and set a hold rating on the stock in a research report on Tuesday, November 7th. One analyst has rated the stock with a sell rating, eight have given a hold rating and fifteen have assigned a buy rating to the company’s stock. The stock currently has an average rating of Buy and an average price target of $86.35.

Shares of CVS Health (NYSE CVS) opened at $71.38 on Monday. The firm has a market cap of $72,621.40, a PE ratio of 12.56, a P/E/G ratio of 1.23 and a beta of 0.89. CVS Health has a 52-week low of $66.45 and a 52-week high of $84.72. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.05 and a quick ratio of 0.55.

CVS Health (NYSE:CVS) last issued its quarterly earnings data on Monday, November 6th. The pharmacy operator reported $1.50 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.49 by $0.01. CVS Health had a net margin of 2.77% and a return on equity of 16.96%. The firm had revenue of $46.18 billion for the quarter, compared to the consensus estimate of $46.17 billion. During the same period last year, the firm posted $1.64 EPS. CVS Health’s quarterly revenue was up 3.5% compared to the same quarter last year. equities analysts predict that CVS Health will post 5.9 earnings per share for the current year.

In other news, EVP Helena Foulkes sold 39,340 shares of CVS Health stock in a transaction that occurred on Friday, September 15th. The shares were sold at an average price of $81.88, for a total value of $3,221,159.20. Following the transaction, the executive vice president now directly owns 84,337 shares of the company’s stock, valued at $6,905,513.56. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO David M. Denton sold 237,078 shares of CVS Health stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $79.65, for a total transaction of $18,883,262.70. Following the completion of the transaction, the chief financial officer now directly owns 141,096 shares in the company, valued at $11,238,296.40. The disclosure for this sale can be found here. Insiders sold a total of 714,125 shares of company stock worth $58,119,381 in the last ninety days. Corporate insiders own 0.61% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the company. Jackson Grant Investment Advisers Inc. grew its position in CVS Health by 0.6% during the second quarter. Jackson Grant Investment Advisers Inc. now owns 2,881 shares of the pharmacy operator’s stock valued at $232,000 after purchasing an additional 18 shares in the last quarter. Keel Point LLC grew its position in CVS Health by 0.7% during the first quarter. Keel Point LLC now owns 3,296 shares of the pharmacy operator’s stock valued at $259,000 after purchasing an additional 22 shares in the last quarter. First City Capital Management Inc. grew its position in CVS Health by 0.3% during the first quarter. First City Capital Management Inc. now owns 12,771 shares of the pharmacy operator’s stock valued at $1,003,000 after purchasing an additional 40 shares in the last quarter. Elefante Mark B grew its position in CVS Health by 0.7% during the second quarter. Elefante Mark B now owns 6,400 shares of the pharmacy operator’s stock valued at $515,000 after purchasing an additional 45 shares in the last quarter. Finally, Traynor Capital Management Inc. grew its position in CVS Health by 1.3% during the second quarter. Traynor Capital Management Inc. now owns 3,676 shares of the pharmacy operator’s stock valued at $290,000 after purchasing an additional 48 shares in the last quarter. 82.24% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “Citigroup Analysts Give CVS Health (CVS) a $76.00 Price Target” was first published by Stock Observer and is the property of of Stock Observer. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.thestockobserver.com/2017/12/07/citigroup-analysts-give-cvs-health-cvs-a-76-00-price-target.html.

CVS Health Company Profile

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Analyst Recommendations for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health Corp and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply